2804595-86-4
Chemical Structure
TPC2-A1-P
- CAS No.: 2804595-86-4
- Formula:C20H21BrF3NO3
- Molecular Weight:460.28
IUPAC Name: 5-(5-bromo-2-(trifluoromethoxy)phenyl)-1-(cyclohexylmethyl)-2-methyl-1H-pyrrole-3-carboxylic acid
InChIKey: INDFMVADKKBSSU-UHFFFAOYSA-N
SMILES: BrC1=CC(C2=CC(C(O)=O)=C(C)N2CC3CCCCC3)=C(OC(F)(F)F)C=C1
Biological Activity: TPC2-A1-P is a powerful and membrane permeable agonist of two pore channel 2 (TPC2) with an EC50 of 10.5 μM. TPC2-A1-P plays its role by mimicking the physiological actions of PI(3,5)P2. TPC2-A1-P also shows higher potency to induce Na2+ mobilisation from TPC2 than TPC-A1-N (HY-131614). TPC2-A1-P can be used to probe different functions of TPC2 channels in intact cells[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
TPC2-A1-P | 99.79% | TPC2-A1-P is a powerful and membrane permeable agonist of two pore channel 2 (TPC2) with an EC50 of 10.5 μM. TPC2-A1-P plays its role by mimicking the physiological actions of PI(3,5)P2. TPC2-A1-P also shows higher potency to induce Na2+ mobilisation from TPC2 than TPC-A1-N (HY-131614). TPC2-A1-P can be used to probe different functions of TPC2 channels in intact cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.47
HY-118790BB-223-carboxyindole metabolite -
Similarity Score 0.46
HY-162044COX-1/2-IN-6 -
Similarity Score 0.46
HY-W345492Methyl-1-(cyclohexylmethyl)-1H-indole-3-carboxylate -
Similarity Score 0.45
HY-100208HC-067047 -
Similarity Score 0.44
HY-W721480HC-067047 hydrochloride -
Similarity Score 0.44
HY-145055HBV-IN-11 -
Similarity Score 0.44
HY-147863HBV-IN-24 -
Similarity Score 0.43
HY-153178HECT E3-IN-1 -
Similarity Score 0.43
HY-162009CaMKK2-IN-1 -
Explore the MedChemAI to find more analogs
References
- [1]. Susanne Gerndt, et al. Agonist-mediated switching of ion selectivity in TPC2 differentially promotes lysosomal function. Elife. 2020 Mar 16;9:e54712. [Content Brief]
- [2]. Gerndt S, et al. Discovery of lipophilic two-pore channel agonists. FEBS J. 2020;287(24):5284-5293. [Content Brief]
- [3]. Xuhui Jin, et al. Targeting Two-Pore Channels: Current Progress and Future Challenges. Trends Pharmacol Sci. 2020 Aug;41(8):582-594. [Content Brief]
